| Schuman, Joel S |
NCT02555436: Management of Glaucoma w/ SLT or Trabecular Stent Bypass Microsurgery Using the Diopsys VEP/PERG Protocols |
|
|
| Not yet recruiting | N/A | 60 | US | Visual Evoked Potential/Pattern Electroretinogram (VEP/PERG) | University of Pittsburgh, Diopsys | Glaucoma | 04/16 | 09/16 | | |
NCT00343746: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging |
|
|
| Recruiting | N/A | 100 | US | | New York University School of Medicine, National Eye Institute (NEI) | Macular Degeneration, Glaucoma, Diabetic Retinopathy | 06/18 | 01/20 | | |
| Recruiting | N/A | 5000 | US | | Wills Eye, National Eye Institute (NEI) | Glaucoma, Macular Disease | 07/29 | 07/29 | | |
| Recruiting | N/A | 45 | Europe, US | Repetitive, Transorbital Alternating Current Stimulation (rtACS), Electrical Stimulation, Sham Repetitive, Transorbital Alternating Current Stimulation (rtACS) | Stanford University, NYU Langone Health, Otto-von-Guericke University Magdeburg, Wills Eye | Glaucoma, Glaucoma, Open-Angle | 12/25 | 12/25 | | |
NCT05325996: Evaluating Home Testing Devices for the Management of Glaucoma |
|
|
| Recruiting | N/A | 50 | US | Standard Automatic Perimetry Humphrey Field Analyzer, SAP HFA, visuALL H, iCare Home Tonometer, Spectralis Optical coherence tomography (OCT) | Wills Eye | Glaucoma, Open-Angle | 12/26 | 12/26 | | |
| Wollstein, Gadi |
NCT02555436: Management of Glaucoma w/ SLT or Trabecular Stent Bypass Microsurgery Using the Diopsys VEP/PERG Protocols |
|
|
| Not yet recruiting | N/A | 60 | US | Visual Evoked Potential/Pattern Electroretinogram (VEP/PERG) | University of Pittsburgh, Diopsys | Glaucoma | 04/16 | 09/16 | | |
NCT00343746: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging |
|
|
| Recruiting | N/A | 100 | US | | New York University School of Medicine, National Eye Institute (NEI) | Macular Degeneration, Glaucoma, Diabetic Retinopathy | 06/18 | 01/20 | | |
| Recruiting | N/A | 5000 | US | | Wills Eye, National Eye Institute (NEI) | Glaucoma, Macular Disease | 07/29 | 07/29 | | |
| Recruiting | N/A | 150 | US | Increasing of intraocular pressure (IC) | NYU Langone Health, National Eye Institute (NEI) | Intraocular Pressure | 05/24 | 05/24 | | |
| Kaufman, David L |
| Active, not recruiting | 3 | 154 | Europe, Canada, US, RoW | Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo | Viridian Therapeutics, Inc., Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/24 | 03/25 | | |
| Terminated | 3 | 409 | Europe, US, RoW | Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo | Dompé Farmaceutici S.p.A | Infectious Pneumonia, Severe COVID-19 | 09/24 | 09/24 | | |
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED) |
|
|
| Active, not recruiting | 3 | 188 | Europe, US, RoW | Veligrotug (VRDN-001), Placebo | Viridian Therapeutics, Inc. | Thyroid Eye Disease | 12/24 | 09/25 | | |
| Recruiting | 3 | 600 | US | Inhaled budesonide and formoterol, Pulmicort Respules (budesonide) and Perforomist (formoterol), Inhaled placebo, aerosolized 0.9% saline | Stanford University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) | Pneumonia, Hypoxemia, Acute Respiratory Failure, COVID-19 Pneumonia | 07/25 | 08/25 | | |
| Active, not recruiting | 3 | 1667 | Europe, Canada, Japan, US, RoW | GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS) | GlaxoSmithKline, Iqvia Pty Ltd | Asthma | 10/25 | 10/25 | | |
|
| Recruiting | 2 | 66 | Europe, US | Reparixin 600mg, REP, Matching Placebo, Control | Dompé Farmaceutici S.p.A, Dompè farmaceutici s.p.a. | Acute Respiratory Distress Syndrome, Adult | 08/25 | 08/25 | | |
| Recruiting | N/A | 740 | Europe, Canada, US, RoW | Respiratory Mechanics, Standard Ventilation Strategy | Unity Health Toronto, Canadian Institutes of Health Research (CIHR), University of Toronto, Applied Health Research Centre | ARDS | 11/25 | 03/26 | | |
| Recruiting | N/A | 80 | US | DESA | State University of New York - Downstate Medical Center | Stroke, Blood Pressure, High | 10/24 | 02/25 | | |
| Martel, Joseph |
UplighTED, NCT06307626: A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults with Thyroid Eye Disease. |
|
|
| Recruiting | 3 | 108 | Europe, Japan, US, RoW | Efgartigimod PH20 SC, Placebo PH20 SC | argenx | Thyroid Eye Disease | 02/26 | 10/27 | | |
NCT06164743: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery |
|
|
| Completed | 2 | 91 | US | VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle | VivaVision Biotech, Inc | Inflammation | 05/24 | 05/24 | | |
| Recruiting | 1/2 | 15 | Europe, US | Gene therapy: GS030-DP AND Medical device: GS030-MD | GenSight Biologics, GENSIGHT-BIOLOGICS | Non-syndromic Retinitis Pigmentosa | 12/22 | 12/25 | | |
| Recruiting | 1/2 | 33 | Europe, US | SPVN06 | SparingVision | Retinitis Pigmentosa | 03/25 | 03/29 | | |
| Active, not recruiting | N/A | 5 | US | PRIMA | Science Corporation, Pixium Vision LLC acts as sponosor in the US on behalf of Pixium Vision SA | Dry Age-related Macular Degeneration | 12/25 | 12/25 | | |
| Dhaliwal, Deepinder |
| Recruiting | 3 | 400 | US | Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment | Epion Therapeutics | Keratoconus | 10/25 | 10/25 | | |
| Conner, Ian |
| Recruiting | 3 | 640 | Europe, Canada, US | Low Energy SLT, Standard Energy SLT | West Virginia University, University of Pittsburgh | Glaucoma and Ocular Hypertension | 06/27 | 08/27 | | |
| Recruiting | 1/2 | 60 | US, RoW | Acetazolamide, Diamox, Placebo | Vishwajit Nimgaonkar, MD PhD, Stanley Medical Research Institute | Schizophrenia, Schizo Affective Disorder | 01/25 | 10/25 | | |
NCT00343746: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging |
|
|
| Recruiting | N/A | 100 | US | | New York University School of Medicine, National Eye Institute (NEI) | Macular Degeneration, Glaucoma, Diabetic Retinopathy | 06/18 | 01/20 | | |
NCT00343473: Novel Diagnostics With Optical Coherence Tomography: Imaging the Anterior Eye |
|
|
| Completed | N/A | 22 | US | | NYU Langone Health, National Eye Institute (NEI) | Fuch's Dystrophy, Corneal Disorders, Prior Surgery | 09/19 | 02/24 | | |
| Recruiting | N/A | 5000 | US | | Wills Eye, National Eye Institute (NEI) | Glaucoma, Macular Disease | 07/29 | 07/29 | | |
| Mitchell, Ellen |
NCT03002597: Visual Information Restoration and Rehabilitation Via Sensory Substitution Technology in Children |
|
|
| Terminated | N/A | 9 | US | BrainPort V200 Device | Ellen Mitchell | Blindness | 06/21 | 06/21 | | |
NCT02815891: A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) |
|
|
| Recruiting | N/A | 15000 | Europe, US | | Target PharmaSolutions, Inc. | Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis | 07/36 | 07/36 | | |
| Truman, Kristy |
NCT00343746: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging |
|
|
| Recruiting | N/A | 100 | US | | New York University School of Medicine, National Eye Institute (NEI) | Macular Degeneration, Glaucoma, Diabetic Retinopathy | 06/18 | 01/20 | | |
| Stone, Merisa |
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 |
|
|
| Recruiting | 3 | 70 | US | RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control | ReGenTree, LLC | Neurotrophic Keratopathy | 07/24 | 11/24 | | |
| Dahlstrom, Rhonda J |
| Active, not recruiting | 3 | 222 | Europe, Canada, US, RoW | Adalimumab (ADA), Adalimumab, Humira, Conventional immunosuppression (CON), Azathioprine, Imuran , Cyclosporine, Methotrexate, Rheumatrex, Mycophenolate, CellCept, Cyclosporine, Sandimmune, Neoral, Tacrolimus, Prograf | JHSPH Center for Clinical Trials | Uveitis | 04/24 | 09/24 | | |
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 |
|
|
| Recruiting | 3 | 70 | US | RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control | ReGenTree, LLC | Neurotrophic Keratopathy | 07/24 | 11/24 | | |
| Recruiting | 3 | 640 | Europe, Canada, US | Low Energy SLT, Standard Energy SLT | West Virginia University, University of Pittsburgh | Glaucoma and Ocular Hypertension | 06/27 | 08/27 | | |
| Recruiting | 1/2 | 33 | Europe, US | SPVN06 | SparingVision | Retinitis Pigmentosa | 03/25 | 03/29 | | |
| Shah, Mahmood |
NCT03349242: Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR) |
|
|
| Completed | N/A | 140 | Europe, Canada, US | | MeiraGTx UK II Ltd, Janssen, LP | Retinitis Pigmentosa | 04/24 | 04/24 | | |
| Jhanji, Vishal |
| Withdrawn | 4 | 50 | US | Cyclosporine, Cequa, Artificial tear, Preservative-free artificial tears | Vishal Jhanji, Sun Pharmaceutical Industries Limited | Dry Eye | 12/23 | 12/23 | | |
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 |
|
|
| Recruiting | 3 | 70 | US | RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control | ReGenTree, LLC | Neurotrophic Keratopathy | 07/24 | 11/24 | | |
NCT05489510: PXL-Platinum 330 in Eyes With Corneal Thinning Conditions |
|
|
| Withdrawn | 1/2 | 300 | US | Pulsed or continuous lighting | Vishal Jhanji | Corneal Thinning, Keratoconus | 12/31 | 12/31 | | |
| Aleman, Tomas |
| Recruiting | 3 | 438 | Europe, Canada, US, RoW | N-acetylcysteine, Placebo | Johns Hopkins University, National Eye Institute (NEI), Duke University, Emory University, Massachusetts Eye and Ear Infirmary, Mayo Clinic, Medical College of Wisconsin, Retina Foundation of the Southwest, Stanford University, University of California, Davis, University of Florida, University of Iowa, University of Miami, University of Michigan, University of Minnesota, University of Oklahoma, University of Southern California, University of Utah, University of Washington, University of Wisconsin, Madison, Vanderbilt University, Vitreo Retinal Associates, PA, University of Houston, Medical University of Graz, McGill University, Universität Tübingen, Centro Medico ABC, Radboud University Medical Center, University of Amsterdam, University Hospital, Basel, Switzerland, University College London Hospitals, Northwestern University, University of Pennsylvania | Retinitis Pigmentosa | 12/28 | 12/28 | | |
NCT05616793: Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) |
|
|
| Recruiting | 1/2 | 15 | US | AAV8.hLCA5 | Opus Genetics, Inc, University of Pennsylvania | LCA5 | 12/24 | 01/28 | | |
| Recruiting | 1/2 | 21 | US | ATSN-201 | Atsena Therapeutics Inc. | X-linked Retinoschisis | 10/25 | 10/29 | | |
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants |
|
|
| Recruiting | N/A | 1500 | Europe, Canada, US, RoW | | Jaeb Center for Health Research, Foundation Fighting Blindness | Inherited Retinal Degeneration, Retinitis Pigmentosa | 12/28 | 12/28 | | |
| DeRosa, Michael J |
| Withdrawn | 4 | 50 | US | Cyclosporine, Cequa, Artificial tear, Preservative-free artificial tears | Vishal Jhanji, Sun Pharmaceutical Industries Limited | Dry Eye | 12/23 | 12/23 | | |
| Recruiting | 1/2 | 63 | US | OCU410 | Ocugen | Geographic Atrophy | 09/25 | 09/25 | | |
| Salay, Melessa |
NCT02555436: Management of Glaucoma w/ SLT or Trabecular Stent Bypass Microsurgery Using the Diopsys VEP/PERG Protocols |
|
|
| Not yet recruiting | N/A | 60 | US | Visual Evoked Potential/Pattern Electroretinogram (VEP/PERG) | University of Pittsburgh, Diopsys | Glaucoma | 04/16 | 09/16 | | |
| Rosin, Boris |
| Recruiting | N/A | 1000 | Europe, US, RoW | Optical coherence tomography (OCT) | University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel | Retinal Dystrophies | 12/24 | 12/25 | | |
Uni-Rare, NCT05589714: Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants |
|
|
| Recruiting | N/A | 1500 | Europe, Canada, US, RoW | | Jaeb Center for Health Research, Foundation Fighting Blindness | Inherited Retinal Degeneration, Retinitis Pigmentosa | 12/28 | 12/28 | | |
| Recruiting | N/A | 1000 | Europe, US, RoW | OCT | University Hospital, Basel, Switzerland, Institute of Molecular and Clinical Ophthalmology Basel, Switzerland | Retinal Dystrophies | 04/22 | 12/22 | | |
| Aubourg, Carla |
NCT05489510: PXL-Platinum 330 in Eyes With Corneal Thinning Conditions |
|
|
| Withdrawn | 1/2 | 300 | US | Pulsed or continuous lighting | Vishal Jhanji | Corneal Thinning, Keratoconus | 12/31 | 12/31 | | |
| Bartizal, Chris |
NCT05555589: Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 |
|
|
| Recruiting | 3 | 70 | US | RGN-259, Tβ4, Thymosin Beta 4, Timbetasin, Placebo, Vehicle Control | ReGenTree, LLC | Neurotrophic Keratopathy | 07/24 | 11/24 | | |
| Anthony, Natalie |
| Recruiting | 1/2 | 33 | Europe, US | SPVN06 | SparingVision | Retinitis Pigmentosa | 03/25 | 03/29 | | |
| Stefko, Susan |
| Active, not recruiting | 3 | 154 | Europe, Canada, US, RoW | Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo | Viridian Therapeutics, Inc., Viridian Therapeutics, Inc. | Thyroid Eye Disease | 07/24 | 03/25 | | |
| Lu, Jason |
| Recruiting | 3 | 640 | Europe, Canada, US | Low Energy SLT, Standard Energy SLT | West Virginia University, University of Pittsburgh | Glaucoma and Ocular Hypertension | 06/27 | 08/27 | | |
| Lamborn, Andrew |
| Recruiting | 1/2 | 33 | Europe, US | SPVN06 | SparingVision | Retinitis Pigmentosa | 03/25 | 03/29 | | |
| Recruiting | 1 | 20 | US | VP-001 | PYC Therapeutics | Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy, RP11 | 05/24 | 05/24 | | |
NCT05573984: Natural History of PRPF31 Mutation-Associated Retinal Dystrophy |
|
|
| Recruiting | N/A | 50 | US, RoW | | PYC Therapeutics | Retinitis Pigmentosa, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Dystrophy Rod, Retinal Dystrophy Rod Progressive | 12/26 | 04/27 | | |
